丘鈦科技(01478.HK)4月攝像頭模組銷售按月減少21.3%
丘鈦科技(01478.HK)公布,4月份,主要產品攝像頭模組銷售數量合計2,986.3萬件,按月及按年分別減少21.3%及11.2%,主要是由於客戶項目週期因素。其他領域攝像頭模組銷售數量按年及按月大幅上升120%及23.5%,主要因來自智能汽車和物聯網(IoT)領域的攝像頭模組需求明顯上升。
月內,指紋識別模組產品銷售數量1,098.2萬件,按月及按年分別增加18.3%及23.6%,歸因集團市場份額有所上升。
今年首四個月,手機攝像頭模組銷售數量總計約1.13億件,按年減少21.8%;指紋識別模組銷量3,310.3萬件,減少5.8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.